Olga Marie Jiodio
Psychiatric/Mental Health · Indianapolis, INNPI 1447995881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,335, 2.6 times the $882 reported in 2022. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$815
- Johnson & Johnson$624
- Vanda Pharmaceuticals Inc.$571
- Neurocrine Biosciences, Inc.$486
- plus $1K from 12 others
What the payments were for
- Food & beverage$5,56993%
- Education$4007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 36 | $1,149 |
| Alkermes, Inc. | 37 | $1,011 |
| Teva Pharmaceuticals USA, Inc. | 31 | $815 |
| Johnson & Johnson | 49 | $624 |
| Vanda Pharmaceuticals Inc. | 19 | $571 |
| Neurocrine Biosciences, Inc. | 32 | $486 |
| AbbVie | 18 | $330 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $327 |
| Supernus Pharmaceuticals, Inc. | 13 | $172 |
| Indivior Inc. | 9 | $169 |
| Lundbeck LLC | 8 | $139 |
| E.r. Squibb & Sons, L.L.C. | 1 | $44 |
| Corium, LLC | 2 | $38 |
| Noven Therapeutics, LLC | 2 | $28 |
| Astellas Pharma US Inc | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,345
- ARISTADA$427
- ABILIFY ASIMTUFII$369
- ABILIFY MAINTENA$369
- REXULTI$354
- Fanapt$231
- AUSTEDO$138
- ARISTADA INITIO$107
How this compares
$5,969 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 159 | $445,300 |
| Abilify MaintenaAripiprazole | 96 | $275,284 |
| IngrezzaValbenazine Tosylate | 34 | $257,656 |
| Invega TrinzaPaliperidone Palmitate | 27 | $187,702 |
| RexultiBrexpiprazole | 56 | $83,310 |
| AustedoDeutetrabenazine | 15 | $74,084 |
| CaplytaLumateperone Tosylate | 27 | $44,693 |
| AristadaAripiprazole Lauroxil | 11 | $36,719 |
| VraylarCariprazine Hcl | 25 | $35,580 |
| Austedo XrDeutetrabenazine | 11 | $35,213 |
| Paliperidone ErPaliperidone | 110 | $33,081 |
| TrintellixVortioxetine Hydrobromide | 48 | $27,063 |
| Risperidone ErRisperidone Microspheres | 22 | $23,495 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $20,385 |
| Fluphenazine Decanoate | 87 | $9,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $624 | $633,002186 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,149 | $358,594152 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $486 | $257,65634 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $815 | $109,29726 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,011 | $57,10424 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $327 | $44,69327 claims |
| AbbVieVraylar | $330 | $35,58025 claims |
| Indivior Inc.Suboxone | $169 | $5,25111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Indianapolis
- Sonya RuedlingerIndianapolis$134K
- Devan GravesIndianapolis$12K
- Clyde YanIndianapolis$9K
- Beth DelamboIndianapolis$7K
- Lindsay RussellIndianapolis$5K
- Nina VoigtIndianapolis$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Trina GreenwaldMarion$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.